IMMU-34 Systemic Immune Suppression in Glioblastoma is Targeted by Concurrent VEGF and PD-1 Inhibition in a Dose-Dependent Manner: Transcriptomic Findings Through CITE-Seq from a Randomized Controlled Trial

Ahmad Ozair; Atulya Khosla; Shreyas Bellur; Michael McDermott; Manmeet Ahluwalia

IMMU-34 Systemic Immune Suppression in Glioblastoma is Targeted by Concurrent VEGF and PD-1 Inhibition in a Dose-Dependent Manner: Transcriptomic Findings Through CITE-Seq from a Randomized Controlled Trial

Ahmad Ozair
, Atulya Khosla
, Shreyas Bellur
, Michael McDermott
, Manmeet Ahluwalia

Research output: Contribution to conference › Presentation

Original language	American English
State	Published - Nov 15 2023
Event	Neuro-Oncology - Duration: Nov 15 2023 → …

Conference

Conference	Neuro-Oncology
Period	11/15/23 → …

Cite this

@conference{d8a393151e5d4105bf81152c4481c654,

title = "IMMU-34 Systemic Immune Suppression in Glioblastoma is Targeted by Concurrent VEGF and PD-1 Inhibition in a Dose-Dependent Manner: Transcriptomic Findings Through CITE-Seq from a Randomized Controlled Trial",

author = "Ahmad Ozair and Atulya Khosla and Shreyas Bellur and Michael McDermott and Manmeet Ahluwalia",

note = "Ozair, A., Alban, T., Grabowski, M., Otvos, B., Bayik, D., Bamashmos, A., Rayman, P., Diaz, M., Khosla, A., Bellur, S., McDermott, M., Reardon, D., Wen, P., Mohammadi, A., Peereboom, D., Lathia, J., \& Ahluwalia, M. (2023). IMMU-34 Systemic Immune Suppression in Glioblastoma is Targeted by Concurrent VEGF and PD-1 Inhibition in a Dose-Dependent Manner: Transcriptomic Findings Through CITE-Seq from a Randomized Controlled Trial. Neuro-Oncology, 25(Supplement\_5), v149-v149. https://doi.org/10.1093/neuonc/noad179.0566; Neuro-Oncology ; Conference date: 15-11-2023",

year = "2023",

month = nov,

day = "15",

language = "American English",

}

TY - CONF

T1 - IMMU-34 Systemic Immune Suppression in Glioblastoma is Targeted by Concurrent VEGF and PD-1 Inhibition in a Dose-Dependent Manner: Transcriptomic Findings Through CITE-Seq from a Randomized Controlled Trial

AU - Ozair, Ahmad

AU - Khosla, Atulya

AU - Bellur, Shreyas

AU - McDermott, Michael

AU - Ahluwalia, Manmeet

N1 - Ozair, A., Alban, T., Grabowski, M., Otvos, B., Bayik, D., Bamashmos, A., Rayman, P., Diaz, M., Khosla, A., Bellur, S., McDermott, M., Reardon, D., Wen, P., Mohammadi, A., Peereboom, D., Lathia, J., & Ahluwalia, M. (2023). IMMU-34 Systemic Immune Suppression in Glioblastoma is Targeted by Concurrent VEGF and PD-1 Inhibition in a Dose-Dependent Manner: Transcriptomic Findings Through CITE-Seq from a Randomized Controlled Trial. Neuro-Oncology, 25(Supplement_5), v149-v149. https://doi.org/10.1093/neuonc/noad179.0566

PY - 2023/11/15

Y1 - 2023/11/15

UR - https://scholarlycommons.baptisthealth.net/se-all-publications/5074

M3 - Presentation

T2 - Neuro-Oncology

Y2 - 15 November 2023

ER -

IMMU-34 Systemic Immune Suppression in Glioblastoma is Targeted by Concurrent VEGF and PD-1 Inhibition in a Dose-Dependent Manner: Transcriptomic Findings Through CITE-Seq from a Randomized Controlled Trial

Conference

Other files and links

Cite this